The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients ...

Matica Biotechnology (Matica Bio), a leading contract development and manufacturing organization (CDMO) for viral vectors, ...

Ascend Advanced Therapies, which has been on an expansion tear since debuting three years ago, inked a deal with EW ...

PTC Therapeutics’ gene therapy, Kebilidi to treat AADC deficiency receives US FDA approval: Warren, New Jersey Friday, November 15, 2024, 10:00 Hrs [IST] PTC Therapeutics, Inc., ...

At a recent meeting on viral vector purification held in Williamsburg ... heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438–1445 (1998).

Developed by PTC Therapeutics, Kebilidi is an adeno-associated virus vector-based gene therapy indicated for the treatment of ...

Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to ...

AAVs have become a crucial tool in gene therapy and bioprocessing, allowing for targeted treatment options. This course offers a comprehensive understanding of their entire lifecycle, from upstream to ...

An epigenetic editing therapy, MDL-101 includes a guide nucleotide targeting the LAMA1 gene — a close homolog of the ...